Assessment and Treatment of Adult Inmates with Attention Deficit Hyperactivity Disorder: Clinical Effectiveness and Guidelines
Authors: Michelle Clark, Lory Picheca


Acknowledgments:

Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantees with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada’s federal, provincial, or territorial governments or any third party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user’s own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada’s health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.
Research Questions

1. What is the clinical effectiveness regarding the diagnosis of adult inmates who may have attention deficit hyperactivity disorder?

2. What is the clinical effectiveness regarding the treatment of adult inmates who are diagnosed with attention deficit hyperactivity disorder?

3. What are the evidence-based guidelines regarding the diagnosis of adult inmates who may have attention deficit hyperactivity disorder?

4. What are the evidence-based guidelines regarding the treatment of adult inmates who are diagnosed with attention deficit hyperactivity disorder?

Key Findings

One randomized controlled trial, six non-randomized studies, and one evidence-based guideline were identified regarding the diagnosis and treatment of adult inmates with attention deficit hyperactivity disorder.

Methods

A limited literature search was conducted on key resources including PubMed, The Cochrane Library (2017, Issue 6), University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. No filters were applied to limit the retrieval by study type. The search was also limited to English language documents published between January 1, 2012 and June 5, 2017. Internet links were provided, where available.

Selection Criteria

One reviewer screened citations and selected studies based on the inclusion criteria presented in Table 1.

Table 1: Selection Criteria

| Population | Q1: Adult inmates who may have attention deficit hyperactivity disorder (ADHD)  
Q2: Adult inmates who have ADHD |
|------------|--------------------------------------------------------------------------------|
| Intervention | Q1, 3: Interventions used to diagnose ADHD  
Q2, 4: Interventions used to treat ADHD (pharmacological and non-pharmacological treatments) |
| Comparator | Q1-2: Any comparator (another intervention or without intervention)  
Q3-4: No comparator required |
| Outcomes | Accurate assessment, effective treatment, guidelines |
| Study Designs | Health technology assessments, systematic reviews, meta-analyses, randomized controlled trials, non-randomized studies, evidence-based guidelines |
Results

Rapid Response reports are organized so that the higher quality evidence is presented first. Therefore, health technology assessment reports, systematic reviews, and meta-analyses are presented first. These are followed by randomized controlled trials, non-randomized studies, and evidence-based guidelines.

One randomized controlled trial, six non-randomized studies, and one evidence-based guideline were identified regarding the diagnosis and treatment of adult inmates with attention deficit hyperactivity disorder. No relevant health technology assessments, systematic reviews, or meta-analyses were identified.

Additional references of potential interest are provided in the appendix.

Overall Summary of Findings

One non-randomised study was undertaken to validate the Substance Transitions in Addiction Rating Scale (STARS) in a prison population. The tool was used to screen inmates for a conduct disorder and was administered in combination with a clinical diagnostic interview for ADHD. The authors determined that there was an association between the use of coping as a way to manage symptoms and the presence of ADHD. A non-randomized study compared the Barkley Adult ADHD Rating Scale (BAARS-IV) to a clinical diagnostic interview. In the study population the BAARS-IV had a sensitivity of 37.9 and a specificity of 96.3. One study investigated the use of the ADHD Self-Rating Scale (ASRS) and diagnostic assessment with a structured interview for incarcerated women in Sweden. In this population, the ASRS demonstrated a sensitivity of 100 and a specificity of 66. The authors concluded the ASRS was a useful screening tool in this population. Another non-randomized study assessed the use of the ASRS in a Canadian prison population. Male federal offenders were assessed with the tool at intake over 14 months. The clinical threshold for ADHD diagnosis was reached in 16.5% of the population.

One RCT examined the use of osmotic-release oral system (OROS) methylphenidate in adult male long-term prison inmates with ADHD. Over five weeks of treatment, symptom severity was decreased and global functioning improved. In a 47 week open-label extension of the RCT, the authors determined that verbal and visuospatial working memory and abstract verbal reasoning showed significant improvements of the total study period. Some quality of life domains improved over time. A third study was conducted to assess the three year outcomes of the original RCT. The authors determined that “methylphenidate-related improvements in ADHD symptoms and psychosocial functioning obtained during the 52-week trial were maintained at 1- and 3-year follow-ups.” At three years, participants who were not receiving methylphenidate reported more substance misuse, functional impairment and ADHD symptoms.

One evidence-based guideline was identified from the National Institute for Health and Care Excellence (NICE). The recommendation was as follows: “Where there may be concern about the potential for drug misuse and diversion (for example, in prison services), atomoxetine may be considered as the first-line drug treatment for ADHD in adults.” (page 24)
References Summarized

Health Technology Assessments
No literature identified.

Systematic Reviews and Meta-analyses
No literature identified.

Randomized Controlled Trials

Non-Randomized Studies


Guidelines and Recommendations

See: 1.7.1.10, page 25
Appendix — Further Information

Review Articles


